Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term Safety and Pharmacodynamics of Ivacaftor in Pediatric CF (<6 Years)
NCT01946412Phase 3Completed
- Sponsor
- Vertex Pharmaceuticals
- Start
- Dec 2013
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 3 trial of ivacaftor in cystic fibrosis (CF), sponsored by Vertex Pharmaceuticals. Started Dec 2013; status: completed.
02
Drugs
ivacaftor
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on NCT01946412.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01946412.